National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings, 38234-38235 [E8-15203]
Download as PDF
<![CDATA[
38234
Federal Register / Vol. 73, No. 129 / Thursday, July 3, 2008 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meetings
mstockstill on PROD1PC66 with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Centers of Excellence in Chemical
Methodologies and Library Development.
Date: July 22–23, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of General Medical
Sciences, Building 45, Room 3AN18,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: C. Craig Hyde, PhD,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health,
Building 45, Room 3AN18, Bethesda, MD
20892, 301–435–3825, Ch2v@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Minority Biomedical Research
Support in Chemistry.
Date: July 28–29, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, Bethesda, MD 20814.
Contact Person: John J. Laffan, PhD,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health,
Natcher Building, Room 3AN18J, Bethesda,
MD 20892, 301–594–2773.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; NIH Pathway to Independence
Awards.
Date: July 29–30, 2008.
Time: 7 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda Hotel, 7335
Wisconsin Avenue, Bethesda, MD 20814.
VerDate Aug<31>2005
16:46 Jul 02, 2008
Jkt 214001
Contact Person: Meredith D. TempleO’Connor, PhD, Scientific Review Officer,
Office of Scientific Review, National Institute
of General Medical Sciences, National
Institutes of Health, 45 Center Drive, Room
3AN12C, Bethesda, MD 20892, 301–594–
2772, templeocm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
Dated: June 26, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–15062 Filed 7–2–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Kidney Diseases
Mentored Career Applications Review.
Date: July 25, 2008.
Time: 3 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Lakshmanan Sankaran,
PhD, Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 755, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7799, ls38oz@nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Frm 00063
Fmt 4703
Sfmt 4703
Dated: June 26, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–15068 Filed 7–2–08; 8:45 am]
BILLING CODE 4140–01–P
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
PO 00000
Special Emphasis Panel; Type 1 Diabetes
Pathfinder Review Meeting.
Date: August 6, 2008.
Time: 3 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: John F. Connaughton, PhD,
Chief, Chartered Committees Section, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 753, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452,
(301) 594–7797,
connaughtonj@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Lesch Nyhan
Disease Interdisciplinary Studies.
Date: July 28, 2008.
Time: 10:30 a.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Robert Wellner, PhD,
Scientific Review Officer, Review Branch,
E:\FR\FM\03JYN1.SGM
03JYN1
Federal Register / Vol. 73, No. 129 / Thursday, July 3, 2008 / Notices
DEA, NIDDK, National Institutes of Health,
Room 757, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, rw175w@nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, AASK Ancillary
Studies.
Date: July 29, 2008.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Robert Wellner, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 757, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, rw175w@nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Insulin Signaling
Interdisciplinary Studies.
Date: July 30, 2008.
Time: 9 a.m. to 11:30 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Robert Wellner, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 757, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, rw175w@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: June 27, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–15203 Filed 7–2–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on PROD1PC66 with NOTICES
Office of the Director, National
Institutes of Health; Office of
Biotechnology Activity; Recombinant
DNA Research; Notice of a Working
Group Meeting of the NIH Blue Ribbon
Panel
There will be a working group
meeting of the NIH Blue Ribbon Panel
to advise on the Risk Assessment of the
National Emerging Infectious Diseases
Laboratories (NEIDL) at Boston
University Medical Center.
The meeting will be held on
Wednesday, July 16, 2008, at the
National Institutes of Health, Building
VerDate Aug<31>2005
16:46 Jul 02, 2008
Jkt 214001
31, 31 Center Drive, Floor 6C, Room 6,
Bethesda, MD 20892 from
approximately 8 a.m. to 1 p.m.
Discussions will focus on risk
communications and the general
principles and strategies for effective
community outreach and engagement.
For further information concerning
this meeting contact Ms. Laurie
Lewallen, Advisory Committee
Coordinator, Office of Biotechnology
Activities, Office of the Director,
National Institutes of Health, Mail Stop
Code 7985, Bethesda, MD 20892–7985,
telephone 301–496–9838, e-mail
lewallla@od.nih.gov.
Background information may be
obtained by contacting NIH OBA by
email oba@od.nih.gov.
Dated: June 26, 2008.
Amy P. Patterson,
Director, Office of Biotechnology Activities,
National Institutes of Health.
[FR Doc. E8–15064 Filed 7–2–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories Which
Meet Minimum Standards To Engage in
Urine Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories currently
certified to meet the standards of
Subpart C of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908),
on September 30, 1997 (62 FR 51118),
and on April 13, 2004 (69 FR 19644).
A notice listing all currently certified
laboratories is published in the Federal
Register during the first week of each
month. If any laboratory’s certification
is suspended or revoked, the laboratory
will be omitted from subsequent lists
until such time as it is restored to full
certification under the Mandatory
Guidelines.
If any laboratory has withdrawn from
the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end,
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
38235
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov and https://
www.drugfreeworkplace.gov.
Mrs.
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 2–
1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were developed
in accordance with Executive Order
12564 and section 503 of Public Law
100–71. Subpart C of the Mandatory
Guidelines, ‘‘Certification of
Laboratories Engaged in Urine Drug
Testing for Federal Agencies,’’ sets strict
standards that laboratories must meet in
order to conduct drug and specimen
validity tests on urine specimens for
Federal agencies. To become certified,
an applicant laboratory must undergo
three rounds of performance testing plus
an on-site inspection. To maintain that
certification, a laboratory must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories which claim to be in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A laboratory
must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA)
which attests that it has met minimum
standards.
In accordance with Subpart C of the
Mandatory Guidelines dated April 13,
2004 (69 FR 19644), the following
laboratories meet the minimum
standards to conduct drug and specimen
validity tests on urine specimens:
ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227, 414–328–
7840/800–877–7016 (Formerly:
Bayshore Clinical Laboratory).
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264.
Advanced Toxicology Network, 3560
Air Center Cove, Suite 101, Memphis,
TN 38118, 901–794–5770/888–290–
1150.
Aegis Sciences Corporation, 345 Hill
Ave., Nashville, TN 37210, 615–255–
2400 (Formerly: Aegis Analytical
Laboratories, Inc.).
Baptist Medical Center-Toxicology
Laboratory, 9601 I–630, Exit 7, Little
Rock, AR 72205–7299, 501–202–2783
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center).
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\03JYN1.SGM
03JYN1
]]>Agencies
[Federal Register Volume 73, Number 129 (Thursday, July 3, 2008)]
[Notices]
[Pages 38234-38235]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-15203]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel, Lesch Nyhan Disease
Interdisciplinary Studies.
Date: July 28, 2008.
Time: 10:30 a.m. to 1 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Robert Wellner, PhD, Scientific Review Officer,
Review Branch,
[[Page 38235]]
DEA, NIDDK, National Institutes of Health, Room 757, 6707 Democracy
Boulevard, Bethesda, MD 20892-5452, rw175w@nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel, AASK Ancillary Studies.
Date: July 29, 2008.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Robert Wellner, PhD, Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 757,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, rw175w@nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel, Insulin Signaling
Interdisciplinary Studies.
Date: July 30, 2008.
Time: 9 a.m. to 11:30 a.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Robert Wellner, PhD, Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 757,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, rw175w@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: June 27, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E8-15203 Filed 7-2-08; 8:45 am]
BILLING CODE 4140-01-P
